Originally published In Press as doi:10.1074/mcp.M500017-MCP200 on February 25, 2005.
Molecular & Cellular Proteomics 4:570-581, 2005.
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc.
Research
Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas*
Gita Ohlsson , ,
José M. A. Moreira ,
Pavel Gromov ,
Guido Sauter¶ and
Julio E. Celis ,
From the Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark DK-2100; and ¶ Division of Molecular Pathology, Institute of Pathology, University of Basel, Basel, Switzerland 4031
Bladder cancer is the fifth most common malignancy in the world and represents the second most common cause of death among genitourinary tumors. Current prognostic parameters such as grade and stage cannot predict with certainty the long-term outcome of bladder cancer, and as a result there is a pressing need to identify markers that may predict tumor behavior. Earlier we identified the adipocyte fatty acid-binding protein (A-FABP), a small-molecular-mass fatty acid-binding protein that functions by facilitating the intracellular diffusion of fatty acids between cellular compartments as a putative marker of progression based on a limited study of fresh bladder urothelial carcinomas (UCs) (Celis, J. E., Ostergaard, M., Basse, B., Celis, A., Lauridsen, J. B., Ratz, G. P., Andersen, I., Hein, B., Wolf, H., Orntoft, T. F., and Rasmussen, H. H. (1996) Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res.56, 47824790). Here we have comprehensively examined the protein expression profiles of a much larger sample set consisting of 153 bladder specimens (46 nonmalignant biopsies, 11 pTa G1, 40 pTa G2, 10 pTa G3, 13 pT1 G3, 23 pT2-4 G3, and 10 pT2-4 G4) by gel-based proteomics in combination with immunohistochemistry (IHC) using a peptide-based rabbit polyclonal antibody that reacts specifically with this protein. Proteomic profiling showed a striking down-regulation of A-FABP in invasive lesions, a fact that correlated well with immunohistochemical analysis of the same samples. The IHC results were confirmed by using a tissue microarray (TMA) containing 2,317 samples derived from 1,849 bladder cancer patients. Moreover, we found that the altered expression of A-FABP in invasive UCs is not due to deregulated expression of peroxisome proliferator-activated receptor (PPAR ), a trans-activator of A-FABP. Taken together, these results provide evidence that deregulation of A-FABP may play a role in bladder cancer progression and suggest that A-FABP could have a significant prognostic value in combination with other biomarkers.
To whom correspondence should be addressed: Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark. Tel.: 45-35257500; Fax: 45-35257721; E-mail: gio{at}cancer.dk and E-mail: jec{at}cancer.dk

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. M. A. Moreira, G. Ohlsson, P. Gromov, R. Simon, G. Sauter, J. E. Celis, and I. Gromova
Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer
Mol. Cell. Proteomics,
January 1, 2010;
9(1):
161 - 177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Schiffer, A. Vlahou, A. Petrolekas, K. Stravodimos, R. Tauber, J. E. Geschwend, J. Neuhaus, J.-U. Stolzenburg, M. R. Conaway, H. Mischak, et al.
Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
Clin. Cancer Res.,
August 1, 2009;
15(15):
4935 - 4943.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. N. Raveendran, K. Silver, L. C. Freeman, D. Narvaez, K. Weng, S. Ganta, and J. D. Lillich
Drug-Induced Alterations to Gene and Protein Expression in Intestinal Epithelial Cell 6 Cells Suggest a Role for Calpains in the Gastrointestinal Toxicity of Nonsteroidal Anti-Inflammatory Agents
J. Pharmacol. Exp. Ther.,
May 1, 2008;
325(2):
389 - 399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Pisitkun, R. Johnstone, and M. A. Knepper
Discovery of Urinary Biomarkers
Mol. Cell. Proteomics,
October 1, 2006;
5(10):
1760 - 1771.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|